@planet_green_co Q1 revs 657% to $6.36M, net profit $0.5M . Legacy chemicals premium tea digital media biotech. Deep research shows turnaround potential from the steps company has taken to maximize its value. Links in thread:
@Hollywallent Expands extensive music and media catalog and operations with new joint venture. Also targeting sports, music, entertainment, TV, motion pictures, broadcast and distribution industries. Strong momentum in intellectual property rights and licensing. Links in thread
@Hollywallent Expands extensive music and media catalog and operations with new collab. Also focuses on sports, music, entertainment, TV, motion pictures, broadcast and distribution industries. Strong momentum in intellectual property rights and licensing. Links in thread:
@Hollywallent Prepares for global growth and expansion of extensive music and media catalog and operations within the sports, music, entertainment, TV, motion pictures, broadcast and distribution industries. Strong momentum in intellectual property and licensing. See links
@Cadiz_Inc On clear path to profitability. Insider buying. Forecast to breakeven in 2 years, projected $45M profit in 2028 with strong 59% average annual growth. Delivering innovative solutions. Future of water is clean and affordable. Links in thread:
@Cadiz_Inc On clear path to profitability. Forecast to breakeven in 2 years, projected $45M profit in 2028 with strong 59% average annual growth. Delivering innovative solutions. Future of water is clean and affordable. Links in thread:
@Hollywallent Prepares for global growth and expansion of extensive music and media catalog and operations within the sports, music, entertainment, TV, motion pictures, broadcast and distribution industries. Strong momentum in intellectual property rights and licensing. See links
@Hollywallent announces Q2 expected consolidated statements. Music catalog ip assets valued by independent firm. See deep research report. Strong momentum in entertainment, intellectual property rights and licensed holdings. Links in thread:
@Cadiz_Inc Shorts about to be underwater. On clear path to profitability. Forecast to breakeven in 2 years, projected $45M profit in 2028 with strong 59% average annual growth. Delivering innovative solutions. Future of water is clean and affordable. Links in thread:
@Cadiz_Inc Squeeze imminent. Future of water is clean and affordable. On clear path to profitability. Analysts forecast breakeven in 2 years, projected US$45M profit in 2028 with strong 59% avg annual growth. Delivering innovative water solutions. Links in thread
@genprex Positive biomarker data published (Trop-2 H-scores 100 , PTEN scores below 100). Encouraging Type 2 diabetes gene therapy. Demonstrates in vivo proof-of-concept for novel diabetes gene therapy. Rejuvenated exhausted beta cells and normalized glucose levels. See links:
@WGRX_Health Q1 revs near $1M with Q2 guidance of $1.77M . Expands direct sales with focus on $70B market for muscle loss from glp weight loss products. Kare joint venture expands access to 200,000 . EinsteinRx Ai platform optimizes dispensing and patient outcomes. Links below:
@Algorhythm_AI Q1 results are off to a strong start with first quarter revenue growing more than 71% sequentially and more than 1,800% year-over-year as SemiCab business continues to scale. Apex SaaS platform positioned strong growth. Links in thread:
@NextNRGinc Q1 results. $21.1M in revs, gross profit triples. Earnings call today at 9am EDT. Ai-powered microgrids respond to disruptions and offer autonomous distributed balanced generation while optimizing for cost and resilience. Links below:
@jonessodaco Q1 results. Revs $12.4M ( 194% yoy), gross profit 179% to $3.9M. Raises 2026 full year revenue guidance to $40M . Expands Costco , CircleK and Walmart national and international distribution. Squeeze starts at $0.74. Links below:
@GTBiopharma 1st human dosing. Advances 3 TriKE candidates. Platform combines precision, potency, and potential for fewer side effects than conventional treatments. GTB-3650 Phase 1 for AML/MDS hits Cohort 4 at 10µg/kg—no safety issues. Oncology market $139B-$268B by 2034. Links
@GTBiopharma$GTBP 1st human dosing. Advanced TriKE next-generation platform combines precision, potency, and potential for fewer side effects than conventional treatments. GTB-3650 Phase 1 for AML/MDS hits Cohort 4 at 10µg/kg—no safety issues. Oncology market $139B-$268B by 2034
@nextplat Q1 revs $9.9M with record 35% gross margins vs 21% in prior year. Reduces expenses 9%. Expects positive net income in 2nd half. $54.3M full year 2025 revs, 340B covered entities, higher margin fulfillment exceeding 6,000 scripts per month. Links below:
@moleculinbio Trial unblinding imminent. ClevelandClinic finds no significant cardiotoxicity. Extends survival by more than 60% in metastatic pancreatic cancer pre-clin models. If mid '26 results of 45 person cohort confirms 40% CRc rate, risk drops. Links below:
@WGRX_Health Targets $14B market with new collab. Kare joint venture expands access to 200,000 . $105M letter of intent to acquire Neuritek. Targets $70B market for muscle loss due to weight loss products. EinsteinRx Ai platform to optimize dispensing and patient outcomes. Links